<code id='BC29BEB384'></code><style id='BC29BEB384'></style>
    • <acronym id='BC29BEB384'></acronym>
      <center id='BC29BEB384'><center id='BC29BEB384'><tfoot id='BC29BEB384'></tfoot></center><abbr id='BC29BEB384'><dir id='BC29BEB384'><tfoot id='BC29BEB384'></tfoot><noframes id='BC29BEB384'>

    • <optgroup id='BC29BEB384'><strike id='BC29BEB384'><sup id='BC29BEB384'></sup></strike><code id='BC29BEB384'></code></optgroup>
        1. <b id='BC29BEB384'><label id='BC29BEB384'><select id='BC29BEB384'><dt id='BC29BEB384'><span id='BC29BEB384'></span></dt></select></label></b><u id='BC29BEB384'></u>
          <i id='BC29BEB384'><strike id='BC29BEB384'><tt id='BC29BEB384'><pre id='BC29BEB384'></pre></tt></strike></i>

          Home / entertainment / hotspot

          hotspot


          hotspot

          author:knowledge    Page View:6
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In